Drug Trial Radar · NCT03829254
A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
Jun 17, 2019
Primary completion
Jul 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- NuCana plcAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/II, dose-escalation and expansion study of NUC-7738 administered by intravenous infusion as a monotherapy and in combination with pembrolizumab. In Phase I, NUC-7738 monotherapy is evaluated across two administration schedules (weekly or fortnightly) in a dose-escalation design in patients with advanced solid tumours. The main objectives are to assess the safety and tolerability of NUC-7738, in addition to establishing the Maximum Tolerated Dose (MTD) and dose administration schedule of NUC-7738 for further exploration in the Phase II part of the study. In Phase II, the selected dose and designated dosing schedule will be further evaluated in dose-confirmation expansion cohorts enrolling a total of approximately 40 additional patients with advanced solid tumours. Based on emerging data, approximately 6 patients with cutaneous melanoma will be enrolled to these expansion cohorts and will receive NUC-7738 monotherapy. A further cohort will assess NUC-7738 in combination with pembrolizumab in approximately 6-12 patients with cutaneous melanoma. Based on efficacy signals observed in the initial melanoma combination cohort, a further expansion cohort will be initiated to expand to a total of 40 patients to allow a powered analysis. In addition, 12 patients with lymphoma (with potential expansion to a total of 25 patients) may be enrolled to receive NUC-7738 monotherapy.
Conditions
- Advanced Cancer
- Lymphoma
- Solid Tumor
- Melanoma
Interventions
NUC-7738Drug
NUC-7738
PembrolizumabDrug
Pembrolizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with dose-limiting toxicitiesTime frame: From the date of consent until 30 days after the last dose of NUC-7738 administered
- Number of patients with treatment-emergent adverse events (CTCAE v5.0)Time frame: From the date of consent until 30 days after the last dose of NUC-7738 administered
- Number of patients with clinically significant laboratory changes (CTCAE v5.0)Time frame: From the date of consent until 30 days after the last dose of NUC-7738 administered
- Number of patients with changes in physical exam, vital signs, and serial electrocardiograms.Time frame: From the date of consent until 30 days after the last dose of NUC-7738 administered
- MTD for NUC-7738 administered via weekly and fortnightly dosing schedules in patients with advanced solid tumoursTime frame: Until completion of Phase I (an average of 1 year)
- Percentage change from baseline in tumour sizeTime frame: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
- Objective response rate (ORR)Time frame: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
- Duration of response (DoR)Time frame: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
- Disease control rate (DCR)Time frame: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
- Duration of stable disease (DoSD)Time frame: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
- Progression free survival (PFS)Time frame: Assessed every 8 weeks following Day 1 up to and including Cycle 12 (each cycle is 14 days) in single-agent cohorts and Cycle 8 in combination cohorts (each cycle is 21 days), moving to every 12 weeks until the end of study (up to 22 months)
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Cambridge University Hospitals NHS Foundation Trust (Addenbrookes Hospital)
Cambridge, United Kingdom · Recruiting
Edinburgh Cancer Centre, Western General Hospital
Edinburgh, United Kingdom · Recruiting
The Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom · Recruiting
University College London Hospital
London, United Kingdom · Recruiting
The Royal Marsden NHS Foundation Trust
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Freeman Hospital
Newcastle, United Kingdom · Recruiting
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom · Recruiting
Lancashire Teaching Hospitals NHS Foundation Trust, Royal Preston Hospital
Preston, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.